Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı tedaviye geçişin etkinliği

Yıl 2020, Cilt: 45 Sayı: 3, 820 - 826, 30.09.2020

Cem Onur Kıraç Suleyman Ipekci Süleyman Baldane Hüseyin Tezcan Levent Kebapcilar

Öz

Amaç: İnsülin tedavisi altındaki kontrolsüz tip 2 diyabetes mellitus hastalarında glisemik kontrolü sağlamak için en sık tercih edilen yöntem insülin dozlarını arttırmaktır. Bu çalışmada, bu grup hastalarda insülin tedavisi yerine eksenatid ile oral antidiyabetik (OAD) kombinasyonunun etkisini değerlendirdik.
Gereç ve Yöntem: 2015-2017 arasında, C-peptid düzeyleri 2 ng/ml’nin üzerinde olan, insülin ve metformin tedavisi altında kontrolsüz seyrederken eksenatid ve OAD tedavisine geçilen 61 hasta çalışmaya alındı. Hastalar kullandıkları insulin rejimlerine göre, sadece bazal insülin, bifazik insülin ve bazal-bolus insülin grubu olarak 3 gruba ayrıldı. Hastaların tedavi değişikliği öncesi ve tedavinin 6. ayında açlık kan şekerleri, HbA1c ve C-peptid düzeylerine bakıldı.
Bulgular: Eksenatid bazlı tedavinin 6. ayında HbA1c düzeylerinde tedavi değişikliği öncesine göre anlamlı azalma görüldü. Çalışmanın sonunda, eksenatid ve OAD tedavisi alan 61 hastanın 14’ünde HbA1c değeri %7’nin altına düştü. Eksenatid ve OAD tedavisiyle açlık kan şekerinde de azalma görüldü.
Sonuç: Bu çalışmada insülin ve metformin tedavisi altındayken kontrolsüz seyreden T2DM hastlarında eksenatid bazlı tedaviye geçişin glisemik kontrolü sağlamakta insülin dozunu arttırmaktan daha iyi bir tedavi seçeneği olduğunu gösterdik.

Anahtar Kelimeler

c-peptide, exenatide, insulin treatment, Type 2 diabetes mellitus

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

yok

Effect of switching insulin treatment to exenatide based therapy in uncontrolled type 2 diabetes mellitus patients

Öz

Purpose: In patients with uncontrolled type 2 diabetes mellitus (T2DM) on insulin therapy, increasing the insulin doses is most commonly preferred as the first choice to achieve glycaemic control. We evaluated the efficacy of initiating exenatide combination with oral antidiabetics (OAD) instead of insulin therapy.
Materials and Methods: We examined all 61 uncontrolled T2DM patients had greater than 2 ng/ml C-peptide levels and were switched from insulin and metformin therapy to exenatide combination with OAD in the period of 2015 – 2017. For examination, the patients were divided into 3 groups according to their insulin regimen as basal insulin alone, biphasic insulin and basal-bolus insulin groups. The fasting blood glucose (FBG), HbA1c and C-peptide levels of the patients were recorded before and at the 6th month of treatment.
Results: After the 6th month of the exenatide-based treatment, results show that the HbA1c levels were significantly lower than which had been evaluated before this treatment. By the end of the study, 14 of the 61 patients treated with exenatide and OAD achieved to decrease the HbA1c levels under 7.0%. FBG also decreased with the exenatide and OAD treatment.
Conclusion: We demonstrated that in order to achieve glycaemic control, exenatide-based therapy could be a better therapeutic option than increasing insulin doses with insulin and metformin treatment in patients who have uncontrolled T2DM with insulin regimens. 

Anahtar Kelimeler

insulin treatment, exenatide, diabetes mellitus

Proje Numarası

yok

Kaynakça

• 1) Chamberlain JJ, Herman WH, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Annals of Internal Medicine. 2017;166(8):572-8.
• 2) Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(2):253-9.
• 3) Shaefer CF, Reid TS, Dailey G, Mabrey ME, Vlajnic A, Stuhr A, et al. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. Postgrad Med. 2014;126:93-105.
• 4) Church TJ, Haines ST. Treatment Approach to Patients With Severe Insulin Resistance. Clin Diabetes. 2016;34:97-104.
• 5) Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36:226-32.
• 6) Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228-34.
• 7) Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9.
• 8) Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485-502.
• 9) Montvida O, Klein K, Kumar S, Khunti K, Paul SK. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab. 2017;19:108-17.
• 10) Bruinstroop E, Meyer L, Brouwer C, van Rooijen DE, van Dam PS. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2018;9:1369-75.
• 11) Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, et al. PRIBA Study Group. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016;39:250-7.
• 12) Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in persons with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care. 2007;30:2767-72.
• 13) Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8:475-87.
• 14) Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in persons with reduced β-cell function. J Diabetes Investig. 2001;4:585-94.
• 15) Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, et al. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus persons? J Clin Med Res. 2014;6:138-44.
• 16) Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese persons with type 2 diabetes. J Diabetes Complicat. 2013;27:87-91.
• 17) A. Lund, F.K. Knop, T. Vilsbøll, Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25:407-14.
• 18) Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries. 2018;38(Suppl 1):1-115.
• 19) Deng H, Lin S, Yang X, Lv J, Luo S, Zeng L, et al. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naive type 2 diabetic patients. J Diabetes. 2018; https://doi.org/10.1111/1753-0407.12883
• 20) Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Clinical review; Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocirnol Metab. 2015; https://doi.org/10.1210/jc.2014-3421
• 21) Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37:225-41.
• 22) Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incıdence and consequences. Diabetes Obes Metab. 2017;19(5):672-81.